Bionic

Exoskeleton Market worth $2.03 billion by 2030 – Exclusive Report by MarketsandMarkets™Exoskeleton Market worth $2.03 billion by 2030 – Exclusive Report by MarketsandMarkets™

Exoskeleton Market worth $2.03 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., May 14, 2025 /PRNewswire/ -- The global exoskeleton market is projected to grow from USD 0.56 billion in…

3 weeks ago
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic PancreasGlucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas

Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes studyRUTHERFORD, N.J., April 16,…

2 months ago
Phantom Neuro Secures $19M Series A Funding Led by Ottobock to Advance Neural Interface Technology for Prosthetics and RoboticsPhantom Neuro Secures $19M Series A Funding Led by Ottobock to Advance Neural Interface Technology for Prosthetics and Robotics

Phantom Neuro Secures $19M Series A Funding Led by Ottobock to Advance Neural Interface Technology for Prosthetics and Robotics

Investment will accelerate clinical trials and commercialization of Phantom X, with Ottobock joining Phantom Neuro's Board of Directors AUSTIN, Texas,…

2 months ago
Beta Bionics to Host Investor Event on June 22, 2025Beta Bionics to Host Investor Event on June 22, 2025

Beta Bionics to Host Investor Event on June 22, 2025

IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the…

2 months ago
Beta Bionics Announces Board Appointment of Gerard MichelBeta Bionics Announces Board Appointment of Gerard Michel

Beta Bionics Announces Board Appointment of Gerard Michel

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of…

2 months ago
California Science Center IMAX Theater presents the West Coast Premiere of “Superhuman Body 3D” Narrated by Academy Award® Winner Matthew McConaughey On March 29, 2025California Science Center IMAX Theater presents the West Coast Premiere of “Superhuman Body 3D” Narrated by Academy Award® Winner Matthew McConaughey On March 29, 2025

California Science Center IMAX Theater presents the West Coast Premiere of “Superhuman Body 3D” Narrated by Academy Award® Winner Matthew McConaughey On March 29, 2025

"Superhuman Body 3D" Explores the Inner Workings of the Human Body and hopes to inspire the next generation of bioengineers…

3 months ago
UroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive® Smart Implant for Stress Urinary Incontinence TreatmentUroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive® Smart Implant for Stress Urinary Incontinence Treatment

UroMems Announces Successful Results in First-Ever Female Clinical Feasibility Study of UroActive® Smart Implant for Stress Urinary Incontinence Treatment

One-year data for the first patient will be presented for the first time during the SUFU meeting in Palm Springs,…

4 months ago
Valencia Technologies Announces Strategic Investment of up to $35 Million and Appointment of James D. Surek as Chief Executive OfficerValencia Technologies Announces Strategic Investment of up to $35 Million and Appointment of James D. Surek as Chief Executive Officer

Valencia Technologies Announces Strategic Investment of up to $35 Million and Appointment of James D. Surek as Chief Executive Officer

Company Positioned for Accelerated Growth with Infusion of Capital and Proven Commercial Leadership VALENCIA, Calif., Feb. 20, 2025 /PRNewswire/ --…

4 months ago
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesBeta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of…

4 months ago